Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

Zheng et al. report water vapor treatment for in-situ n-doping of ZnMgO, enabling ideal ohmic electron transport and hole blockage as the electron injection layer for quantum dot light-emitting ...